Actualités

CXMT is China’s largest DRAM maker and ranks fourth globally. The IPO could raise 66.6 billion yuan, making it China’s second-largest ever.

The company is fulfilling its ambitions to become an "end-to-end space company."

In the quarter ended June 30, 2026, APA completed a long-running share repurchase program launched in 2018, cumulatively buying back about 100.93 million shares for roughly US$3.31 billion, including 2.8 million shares for US$98.7 million in the most recent tranche. These buybacks, alongside recent insider selling and sector-wide sensitivity to geopolitical tensions in the Strait of Hormuz, highlight how capital returns, management behavior, and external oil supply risks are all influencing...

According to Koyfin data, the 12-month average price target for POET Technologies is $17.50, implying nearly 99% upside from its last close.

Tesla is driving head-on into a more uncertain future, and if investors aren't prepared to accept that risk, this luxury automaker might be just the company to check out instead.

Recent price move puts Nutrien in the spotlight Nutrien (TSX:NTR) moved higher on July 13, 2026, with the stock gaining 3.3% to $67.60. This price action has brought fresh attention to its valuation and the balance between recent momentum and underlying fundamentals. See our latest analysis for Nutrien. That single day move in Nutrien comes on top of a 7 day share price return of 4.1% and a year to date share price return of 11.2%. The 1 year total shareholder return of 21.4% indicates recent...

In a Stocktwits poll that sought to gauge which names would post the best performance over the next 12 months, nearly half the users polled picked CrowdStrike as the clear winner.

Don't wait until clinical milestones send their share prices soaring.

Retail traders plan to buy dips as competition from Meta and valuation concerns pressure the sector.

FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET fusion solid tumors. The decision shifts selpercatinib from accelerated to traditional approval and broadens its labeled use across multiple tumor types. The update reinforces Eli Lilly's (NYSE:LLY) position in oncology and opens new commercial and clinical avenues for the drug. Eli Lilly, known for its oncology and biopharma portfolio, now has a fully approved RET...

The gains come after weeks of volatility due to shifting views on memory durability and the recent escalation in the U.S.-Iran war.

And Goldman Sachs may be right.

The investor said a combined company could use one balance sheet and capital structure to fund Elon Musk’s broader ambitions.

Asian shares mostly rose Wednesday, tracking a rally on Wall Street following a report that showed U.S. inflation was not as bad last month as economists expected. Shares in computer chipmaker SK Hynix rose 9.4%, while those of Samsung Electronics surged 6.1%. Hong Kong's Hang Seng edged up 1.5% to 24,701.10, while the Shanghai Composite lost 0.2% to 3,957.79 after the Chinese government reported the economy expanded at a 4.3% annualized pace in April-June, slowing sharply from 5% in the first quarter of the year.

Shares of the three large U.S. banks surged on Tuesday after posting strong second-quarter earnings.

Payments company Stripe and private ‌equity firm Advent International ‌have made a joint offer to ​acquire PayPal Holdings Inc for $60.50 per share, in a deal that would value the payments ‌company at ⁠more than $53 billion, two people familiar with the ⁠matter said. The offer, submitted earlier this month, is backed by ​about $50 billion ​in committed ​financing from banks, ‌the people said, and represents around a 28% premium to PayPal's closing share price on Tuesday. ​Advent declined to comment, ‌while PayPal and Stripe ​did ​not immediately respond to Reuters requests for comment.

Corporate dealmaking is booming.

Leading cryptocurrencies rallied alongside stocks on Tuesday following cooler-than-expected inflation numbers, despite elevated geopolitical tensions remaining in place. Cryptocurrency24-Hour Gains +/-Price (Recorded at 9:25 p.m. EDT)Bitcoin (CRYPTO: BTC)+3.50%$64,752.40Ethereum (CRYPTO: ETH) +4.72%$1,876.36XRP (CRYPTO: XRP) +3.52%$1.10Solana (CRYPTO: SOL) +2.93%$77.59Dogecoin (CRYPTO: DOGE) +2.64%$0.07403 Crypto Market Rallies Bitcoin hit $65,000 for the first time in over three weeks, while Et

The artificial intelligence chip trade is not stopping at GPUs. Micron Technology (MU) shares rose on July 14 after KeyBanc raised its price target on the memory-chip maker, citing tighter supply and higher prices for DRAM, NAND and high-bandwidth memory, or HBM. Micron stock was recently trading ...

REET owns real estate around the world, while ICF owns only the biggest names in U.S. property. Here is what that distinction means for your portfolio.

The semiconductor equipment maker topped quarterly estimates and forecast fiscal 2027 revenue far above Wall Street expectations.

Cadence leads in 2nm partnerships while Synopsys scales broader capabilities, but their financial profiles and risk exposures diverge sharply.

NICE offers proven profitability and growing cloud momentum, while Twilio's headline growth numbers deserve a closer look before you buy in.

Micron and SK Hynix are two of the leading companies fueling the artificial intelligence (AI) memory boom this year.

The Writers Guild of America became the latest group to challenge Paramount's $81 billion acquisition of Warner Bros. Discovery on Tuesday, filing a lawsuit that seeks to block the merger on the grounds it would cause “specific harm” to movie and TV writers working across the U.S. A Paramount-Warner merger “threatens the economic and creative health of the American entertainment industry,” reads Tuesday's federal complaint, which was filed by both the Writers Guild of America West and Writers Guild of America East (jointly the WGA). “This proposed combined entity would be the largest employer of writers, with tremendous power to suppress our wages, eliminate opportunities for emerging writers, cut jobs across the industry, and produce less programming," WGAE President Tom Fontana said in a statement.

SoundHound stock used to be quite expensive, but it's starting to look attractive.

It may not be the big windfall that you'd expect for oil stocks.

Pfizer, trading as NYSE:PFE, received FDA approval for a platinum-free Padcev-Keytruda regimen in muscle-invasive bladder cancer. The regimen is approved as both neoadjuvant and adjuvant therapy for adult patients, regardless of cisplatin eligibility. This decision expands use of the combination across a broader bladder cancer population and introduces a new treatment option. For investors watching Pfizer at a share price of $24.25, this approval adds a fresh development to the oncology...

A number of stocks jumped in the afternoon session after a cooler-than-expected June inflation report and a surprise capital expenditure warning from IBM appeared to validate AI hardware demand.

Rithm (RITM) closed the most recent trading day at $9.22, moving +1.65% from the previous trading session.